<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00981786</url>
  </required_header>
  <id_info>
    <org_study_id>A434</org_study_id>
    <nct_id>NCT00981786</nct_id>
  </id_info>
  <brief_title>24-Hour Intraocular Pressure With Brinzolamide/Timolol Versus Brimonidine/Timolol</brief_title>
  <official_title>Quality of 24-hour Intraocular Pressure Control Obtained With the Brinzolamide/Timolol Fixed Combination Compared With the Brimonidine/Timolol Fixed Combination When Added to Travoprost Monotherapy in Subjects With Open-angle Glaucoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aristotle University Of Thessaloniki</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Aristotle University Of Thessaloniki</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed crossover study will compare for the first time the quality of 24-hour
      intraocular pressure control with the combination of travoprost and brinzolamide/timolol
      compared with travoprost and brimonidine/timolol in glaucoma patients insufficiently
      controlled with travoprost. This comparison may determine the real efficacy of the two fixed
      combinations when added to the prostaglandin. The design of the proposed study should
      facilitate a better understanding of the role of these medications in glaucoma management.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean 24-hour intraocular pressure</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fluctuation of 24-hour intraocular pressure</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>Brinzolamide/Timolol therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Chronic therapy for 3 months with brinzolamide/timolol drops given twice daily added to travoprost drops</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Brimonidine/Timolol therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Chronic therapy for 3 months with brimonidine/timolol drops given twice daily added to travoprost drops</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brimonidine/timolol fixed combination drops added to travoprost</intervention_name>
    <description>twice daily administration</description>
    <arm_group_label>Brinzolamide/Timolol therapy</arm_group_label>
    <arm_group_label>Brimonidine/Timolol therapy</arm_group_label>
    <other_name>Combigan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brinzolamide/timolol fixed combination drops added to travoprost</intervention_name>
    <description>twice daily dosing</description>
    <arm_group_label>Brinzolamide/Timolol therapy</arm_group_label>
    <arm_group_label>Brimonidine/Timolol therapy</arm_group_label>
    <other_name>Azarga</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient has open-angle glaucoma and is older than 29 years

          -  Patients should exhibit typical disc, or field changes and an untreated morning IOP
             greater than 25 mm Hg

          -  Patients are treated for at least 3 months with travoprost and should have
             demonstrated at least a 20% morning IOP reduction

          -  Patient deemed by PI to require adjunctive therapy to obtain desired target IOP

          -  Patient should exhibit IOP greater than 18 mm Hg on travoprost monotherapy (2 separate
             IOP readings at 10:00)

          -  Patient has mild to moderate glaucoma (field loss more than 16 dB; cupping 0.8 or
             less)

          -  Distance best corrected Snellen visual acuity at least 0.1

          -  No contraindications to travoprost, brimonidine, brinzolamide and Î²-blockers

          -  No history of lack of response (&lt;10% morning IOP reduction) to any medication

          -  Patient can understand the instructions and adhere to medications

        Exclusion Criteria:

          -  Female patient of childbearing potential or lactating mother

          -  History of trauma, inflammation, surgery

          -  History of past use of steroids (within 2 months), severe dry eyes and use of contact
             lenses

          -  Signs of ocular infection, except blepharitis

          -  Evidence of corneal abnormality that may affect IOP measurements etc

          -  Closed angle

          -  History of non-compliance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>29 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anastasios G Konstas, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Glaucoma Unit, 1st University Department of Ophthalmology</affiliation>
  </overall_official>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 16, 2009</study_first_submitted>
  <study_first_submitted_qc>September 21, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2009</study_first_posted>
  <last_update_submitted>May 9, 2014</last_update_submitted>
  <last_update_submitted_qc>May 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aristotle University Of Thessaloniki</investigator_affiliation>
    <investigator_full_name>AGP Konstas</investigator_full_name>
    <investigator_title>Professor in Ophthalmology</investigator_title>
  </responsible_party>
  <keyword>24-hour IOP control</keyword>
  <keyword>brinzolamide/timolol</keyword>
  <keyword>brimonidine/timolol</keyword>
  <keyword>travoprost</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Timolol</mesh_term>
    <mesh_term>Brimonidine Tartrate</mesh_term>
    <mesh_term>Travoprost</mesh_term>
    <mesh_term>Brinzolamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

